53 reports

It is also being evaluated for the treatment of Crohn' s disease, psoriatic arthritis, and asthma.

  • Arthritis
  • Cancer Immunotherapy
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Also frequently prevalent in this study were depression (##%), asthma (##. ##%), malignancies (##. ##%) and chronic obstructive pulmonary disease (##. ##%) (Dougados et al., 2013).

  • Arthritis
  • World
  • Market Size
  • Johnson & Johnson
  • Novartis AG

Rheumatoid arthritis

4546 5000 3864
  • PREVALENCE OF SELECTED CO-MORBIDITIES REPORTED IN THE INTERNATIONAL COMORA STUDY, BY REGION, 2014
  • Arthritis
  • Europe
  • Japan
  • Pfizer Inc.
  • Roche Group
  • 18.1 INTRODUCTION
  • SWITZERLAND HIP RECONSTRUCTION DEVICES MARKET, BY SURGERY TYPE,

IN SWITZERLAND, DISABILITY DUE TO OSTEOPOROSIS IS GREATER THAN THAT CAUSED BY CANCERS (WITH THE EXCEPTION OF LUNG CANCER) AND IS COMPARABLE OR GREATER THAN THE DISABILITY CAUSED BY VARIETY OF CHRONIC NONCOMMUNICABLE DISEASES, SUCH AS RHEUMATOID ARTHRITIS, ASTHMA, AND HIGH BLOOD PRESSURE-REL

  • Arthritis
  • Asia
  • Europe
  • Smith & Nephew Plc
  • Zimmer Biomet Holdings, Inc.
  • 7 Appendix

Many physicians use MTX for its steroid-sparing properties in patients with asthma and patients who have side effects related to corticosteroid use.

  • Arthritis
  • Therapy
  • World
  • Market Size
  • Remicade group
  • 18.1 INTRODUCTION
  • SWITZERLAND HIP RECONSTRUCTION DEVICES MARKET, BY SURGERY TYPE,

IN SWITZERLAND, DISABILITY DUE TO OSTEOPOROSIS IS GREATER THAN THAT CAUSED BY CANCERS (WITH THE EXCEPTION OF LUNG CANCER) AND IS COMPARABLE OR GREATER THAN THE DISABILITY CAUSED BY VARIETY OF CHRONIC NON-COMMUNICABLE DISEASES, SUCH AS RHEUMATOID ARTHRITIS, ASTHMA, AND HIGH BLOOD PRESSURE-RE

  • Arthritis
  • Asia
  • Europe
  • Forecast
  • Zimmer Biomet Holdings, Inc.
  • PIPELINE BY PARADIGM BIOPHARMACEUTICALS LTD, H1 2017
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2017

Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Osteoarthritis, Allergic Asthma, Arthralgia, Arthritis, Edema and Seasonal Allergic Rhinitis.

  • Arthritis
  • Chronic Pain
  • Clinical Trial
  • Therapy
  • Galapagos NV
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Glomerulonephritis, Hepatocellular Carcinoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Irritable Bowel Syndrome, Kidney Fibrosis,

  • Arthritis
  • Cardiovascular Drug
  • Hepatitis
  • Therapy
  • Can-Fite BioPharma Ltd.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016

Asthma ## ## Allergic Rhinitis ## ## Arthritis ## ## Edema ## ## A Disintegrin And Metalloproteinase With Thrombospondin Motifs ## (A Disintegrin And Metalloproteinase With Thrombospondin Motifs ## or Aggrecanase ## or ADMP## or ADAMTS## or EC ##. ##. ##. ) - Pipeline Products Glance LATE STAGE PRODUCTS CO

  • Arthritis
  • Pharmaceutical
  • Vaccine
  • World
  • Product Initiative

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Arthritis
  • Cancer
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • Number of Products under Development by Indications, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017

The company offers its products for the treatment of airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases of the lung.

  • Arthritis
  • Europe
  • United States
  • Product Initiative
  • Pfizer Inc.

The primary outcome measure of the study is to assess the improvement in the severity of asthma as measured by change in the asthma control questionnaire (ACQ) score.

  • Arthritis
  • Europe
  • United States
  • World
  • Novartis AG
  • CELLULAR BIOMEDICINE RAISES USD19.6 MILLION IN PRIVATE PLACEMENT OF SHARES
  • ACQUISITION

The company' s product portfolio includes clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases.

  • Arthritis
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Cellular Biomedicine Group Inc.

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Arthritis
  • Blood Disease
  • United States
  • Product Initiative
  • Incyte Corporation
  • Number of Products under Development by Indication, H2 2017
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

It is in preclinical stage for the treatment of allergic asthma and heart failure.

  • Arthritis
  • Pharmaceutical
  • Therapy
  • Australia
  • Product Initiative

Orbis has preclinical pipeline indications for pathologies including cancer, bronchiolitis, Eczema, atopic dermatitis, nephrotic syndrome, HIV, asthma, buninectomy, head and neck cancers, steroid responsive inner ear conditions, chest congestion, hemorrphoidectomy; as well as for post-surgi

  • Arthritis
  • Pharmaceutical
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

Interleukin-##A (IL-##A) is a CD##+ T cell-derived cytokine that promotes inflammatory responses and is elevated in rheumatoid arthritis (RA), asthma, multiple sclerosis, psoriasis, and transplant rejection.

  • Arthritis
  • Autoimmune Disease
  • United States
  • Product Initiative
  • Novartis AG
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Projects
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..1), H2 2017

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Arthritis
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

As of February 2006, it was in Phase II stage of development for mild asthma.

  • Arthritis
  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • United States
  • Arthritis
  • Cardiovascular Drug
  • World
  • Product Initiative
  • Can-Fite BioPharma Ltd.
  • PIPELINE BY REGENERON PHARMACEUTICALS INC, H2 2017

Regeneron is also developing various product candidates in clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases.

  • Arthritis
  • Chronic Pain
  • United States
  • World
  • Pfizer Inc.
  • R&D Progress
  • DALAZATIDE - DRUG PROFILE

AbbVie is also evaluating the potential of this biologic in Crohn' s disease, psoriatic arthritis, and asthma.

  • Arthritis
  • Autoimmune Disease
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • OSTEOARTHRITIS - PIPELINE BY ORTHOCYTE CORP
  • OSTEOARTHRITIS - PIPELINE BY ONO PHARMACEUTICAL CO LTD

The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, anti-infectives, NSAIDs, anti-TB and cephalosporins.

  • Arthritis
  • United States
  • Company
  • Product Initiative
  • Amgen Inc.
  • PIPELINE BY REGENERON PHARMACEUTICALS INC, H1 2017

Regeneron is also developing various product candidates in clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases.

  • Arthritis
  • Chronic Pain
  • United States
  • Product Initiative
  • Pfizer Inc.
  • CKD-506 - DRUG PROFILE
  • INV-17 - DRUG PROFILE

As of November 2014, it was in Phase II stage for asthma.

  • Arthritis
  • Therapy
  • Company
  • Product Initiative
  • Pfizer Inc.
  • SYNTHETIC PEPTIDES FOR ALLERGIC ASTHMA AND RHEUMATOID ARTHRITIS - DRUG PROFILE
  • RHEUMATOID ARTHRITIS - PIPELINE BY ANGES MG INC, H2 2016
  • Arthritis
  • Chronic Disease
  • Pathology
  • Research And Development
  • Pfizer Inc.
  • SMALL MOLECULE TO INHIBIT PDE4B AND TNF ALPHA FOR ASTHMA, COPD AND UVEITIS - DRUG PROFILE
  • DRUGS TO INHIBIT ALDOSE REDUCTASE FOR IMMUNOLOGY, OPHTHALMOLOGY, INFECTIOUS DISEASE, METABOLIC AND RESPIRATORY DISORDERS - DRUG PROFILE
  • Arthritis
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • ENKO 1 - PRODUCT DESCRIPTION

It offers products and vaccines that are used in the treatment of chronic kidney disease, Parkinson' s disease, asthma, hemophilia, obesity, chronic obstructive pulmonary disease (COPD) and chemotherapy-induced nausea and vomiting, among others.

  • Arthritis
  • Clinical Trial
  • United States
  • Company
  • GlobalData's company
  • PERCENTAGE OF SALES (BASED ON CERTAIN CONDITIONS SPECIFIED IN THE CONTRACT) AS A CO-PROMOTION FEE FROM PFIZER.

The drug candidate was also under development for asthma.

  • Arthritis
  • Autoimmune Disease
  • R&D
  • Research And Development
  • Pfizer Inc.
  • REJOIN - DRUG PROFILE
  • REJOIN - DRUG PROFILE

The company' s product portfolio includes clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases.

  • Arthritis
  • Cell Therapy
  • United States
  • World
  • Product Initiative